EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

EnteroBiotix announced that the first patient has been dosed in a multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of IBS.

EnteroBiotix, a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its Board of Elmar Schnee as Executive Chairman.

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

EnteroBiotix today announced that it has been granted a Manufacturer’s licence for Investigational Medicinal Products (IMP) by the Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture microbiome product candidates for clinical trials. The facility also incorporates an in-house QC hub and analytical department.

EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director.

EnteroBiotix is pleased to announce that the Company has received full registration of their trademark “Number 2”. The Number 2 brand forms a core part of the Company’s strategy to control the supply chain for its Broad Spectrum Microbiota™ therapeutics.

Watch an interview with our Founder and CEO Dr. James McIlroy, where he shares our vision for mastering the microbiome to transform lives of patients.